BPC-157 vs TB-500: the evidence and regulatory records compared

Prepared by: Research Desk. Sources are linked for verification.

"BPC-157 vs TB-500" is one of the most common comparison searches in the peptide space. The two names travel together on forums and in marketing copy. Their records, however, are not the same, and for TB-500 the documented record is especially thin. This page sets the two side by side using only what our listed sources support. Where a claim about TB-500 circulates widely but our sources don't confirm it, we mark it unverified rather than repeat it.

This page compares records. It doesn't discuss combining the two, and it doesn't repeat the full regulatory history of BPC-157, which is on our page with BPC-157's dated regulatory record.

Quick comparison table

Status checked: 18 October 2026.

What each molecule is

BPC-157 is a synthetic pentadecapeptide, a chain of 15 amino acids. The 2025 systematic review by Vasireddi and colleagues describes it as derived from a protein found in human gastric juice [6]; that is the review's summary of the earlier literature rather than original biochemical work. Most early research came from a single group, and the same review found that 35 of the 36 studies it included were preclinical [6]. Our BPC-157 evidence guide covers its origin and the animal literature in detail.

TB-500 is the harder of the two to pin down from primary sources. The WADA Prohibited List places it under thymosin-β4 derivatives [1], which tells us how the anti-doping regulator classifies it. Beyond that classification, common online descriptions of TB-500's exact sequence, its relationship to the full thymosin β-4 protein and its proposed mechanisms are unverified here, because none of our listed sources documents them. We'd rather leave a gap than fill it with marketing copy.

One distinction matters throughout this page. "Thymosin β-4" (the name used in the knee-pain paper [4]) and "TB-500" (the name used by WADA and on the FDA meeting agenda [1][2]) aren't interchangeable labels in the sources. We report each source's wording as it appears.

Human evidence: what exists for each

BPC-157

The most complete independent assessment is the 2026 systematic review by Poolton and colleagues. It searched databases and ClinicalTrials.gov up to June 2026 and found three human studies with 30 participants in total. All were judged to be of poor methodological quality, and overall certainty of evidence was rated very low [5]. The authors concluded that BPC-157 "should not be used clinically in humans outside ethically approved, regulated, high-quality clinical trials" [5].

The 2025 orthopaedic review reached a similar picture from a different angle. Of 36 included studies, one was clinical [6].

TB-500

We found no dedicated human study of TB-500 among our sources. The only point where a thymosin β-4 product enters the published human data is the 2021 retrospective knee-pain series by Lee and Padgett [4]. The authors report on people who had received BPC-157 for knee pain either alone or combined with thymosin β-4. According to the authors, 16 people were reached by phone, of whom 12 had received BPC-157 alone [4].

That design can't say anything specific about thymosin β-4:

• It was retrospective, with no control group [4].

• Outcomes were collected by telephone recall, and the authors note that no specific tools were used to measure function or quality of life [4].

• The group that received the combination was small, and the report doesn't isolate any effect of thymosin β-4 from BPC-157.

• Participants had many different causes of knee pain [4].

So the honest summary is that BPC-157 has a very small, very low-certainty human record [5], and TB-500 has, as far as our sources show, effectively none of its own.

FDA: the July 2026 compounding advisory committee session

FDA's Pharmacy Compounding Advisory Committee met on 23–24 July 2026. As listed on FDA's meeting page, on 23 July the committee discussed BPC-157 bulk substances (free base and acetate) being considered for the 503A bulks list, which governs what traditional compounding pharmacies may use. The use FDA evaluated for BPC-157 was ulcerative colitis [2]. The same page lists TB-500 for that session, along with KPV and MOTS-c [2]. These details reflect the meeting page as we read it on the date checked; FDA can revise meeting materials, and we'll re-confirm them against the official minutes.

What we can and can't say:

• Both molecules were on the same day's agenda [2]. That's the extent of the shared FDA record we can document.

• For TB-500, we haven't verified from an official record which use was nominated or how the committee voted. Those details are unverified.

• For BPC-157, we also haven't independently confirmed the vote outcome from official minutes.

• Advisory committee votes are advice. FDA makes final decisions separately, and any listing would apply to the specific substance, use and route reviewed. It wouldn't make either molecule an approved drug.

We'll update this comparison when we've reviewed the official minutes.

FDA's documented concerns about BPC-157

FDA maintains a page of bulk substances nominated for compounding that it believes may present significant safety risks [3]. On the version we reviewed, BPC-157 sits among substances previously in category 2 whose nominations were withdrawn by the nominators. FDA's entry still records that compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration" and "may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization", and that the agency "lacks sufficient information to know whether the drug would cause harm when administered to humans" [3].

We couldn't confirm an equivalent TB-500 entry from our sources, so the table marks it as unverified. That absence isn't evidence of safety. It only means we can't document an FDA statement either way.

WADA: S0 vs S2 on the Prohibited List

Both molecules are banned in WADA-code sport at all times, in and out of competition, but under different sections [1]:

• BPC-157: S0 Non-Approved Substances. It is named explicitly. S0 covers substances "with no current approval by any governmental regulatory health authority for human therapeutic use" [1].

• TB-500: S2. It is listed among thymosin-β4 derivatives in the section for peptide hormones, growth factors, related substances and mimetics [1].

For an athlete subject to testing, the practical outcome is the same: both are prohibited at all times [1]. The difference is in classification. S0 is a catch-all for unapproved substances, while the S2 listing reflects WADA's placement of TB-500 with growth-factor-related substances. The section heading doesn't establish any particular effect in people.

Safety unknowns common to both

The two molecules share three gaps:

1. No controlled human safety data. For BPC-157, the full human record is three poor-quality studies [5]. For TB-500, our sources show no dedicated human study at all.

2. Unregulated products. The 2025 review notes that adverse effects are possible "due to unregulated manufacturing, contamination, or unknown clinical safety" [6]. FDA's concerns about impurities and API characterization [3] are written about BPC-157, but the underlying problem of unverified content applies to any product sold outside pharmacy oversight.

3. Unknown interactions. The only human data involving both substances come from a retrospective series that wasn't designed to assess safety [4].

Why the two are so often discussed together

The pairing is driven by circumstance more than by shared evidence. Both are promoted in the same online circles for musculoskeletal injuries. They appear together in the 2021 knee-pain series [4], on the same FDA advisory committee agenda [2] and on the same WADA list [1]. None of that shows they work similarly or that either works in people. It shows they share a market and a regulatory spotlight. We deliberately leave questions about combined use out of scope.

Further reading: books on doping and sports science

Readers comparing banned substances often want the longer story: how anti-doping rules developed, how testing laboratories work, and why some compounds become popular in sport before any trial data exist. Good books on this history put any single substance in context.

When choosing a title, these neutral criteria separate useful books from sensational ones:

• Sourcing. Look for endnotes or a bibliography citing official reports, court records and peer-reviewed papers.

• Author background. Investigative journalists, sports scientists and former testing-lab staff each bring different strengths. Look at what the author can actually document.

• Publication date. Anti-doping rules change every year, so a recent edition matters for anything regulatory.

• Format and price. Hardcover, e-book and audiobook editions vary widely in price. Library availability is worth a look too.

We list only books, never products for personal use, and our evidence ratings are unaffected by any commission.

Details on how links are labelled and how the site is funded are on our about this site page.

Summary

BPC-157 and TB-500 are often presented as a matched pair, but the records differ. BPC-157 has a small, very low-certainty human evidence base [5], documented FDA safety concerns [3] and an explicit S0 listing [1]. TB-500 has, in our sources, no dedicated human study, an S2 listing as a thymosin-β4 derivative [1], and a place on the 23 July 2026 FDA advisory committee agenda [2]. Its other FDA details remain unverified. For both, the gap between online claims and published evidence is wide.

Last updated: 18 October 2026.

Not medical advice. This page reports published research and regulatory records for information only.

Research-only notice: Content on this site is provided for research and educational purposes only and is not intended for human use. It is not medical advice.

Translation notice: Some content on this site may have been machine-translated using Google Translate and may contain errors.